This Stock Could Soar by Nearly 300%, Says Wall Street

Companies with multibagger potential can be hard to find in the stock market, and some might be tempted to turn to Wall Street analysts for ideas and inspiration. That's not necessarily a bad move. But investors should always do their due diligence before pressing the buy button, regardless of the opinion of experts.

With that in mind, let's consider one company the Street is bullish on right now: small-cap biotech Provention Bio (NASDAQ: PRVB). This drugmaker's shares could soar by almost 300% if it hits Wall Street's average price target of $16.42. Does Provention Bio have what it takes? Let's dig in.